Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The importance of persistence in cancer drug development
Susan Galbraith, head of Oncology Research & Development at AstraZeneca, discusses the opportunities oncologists can’t walk away from, including HER2, antibody–drug conjugates and earlier intervention.
Frustrated by the lack of tools in the cancer toolbox, Susan Galbraith, a clinical oncologist, made the jump to industry in 2001. For the next 20 years she focused on translational and early-stage oncology, first at Bristol Myers Squibb and then at AstraZeneca. Then in June, she stepped up to oversee everything from cancer drug discovery to late-stage development at AstraZeneca, as Executive Vice President of Oncology Research & Development.